J. Marty Tenenbaum, PhD, Chairman
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006), and Medstory (sold to Microsoft in 2007). He currently serves on the boards of Efficient Finance, Patients Like Me, and the Public Library of Science (PLoS).
Dr. Tenenbaum is a fellow and former board member of the Association for the Advancement of Artificial Intelligence (AAAI), and a former consulting professor of Computer Science at Stanford. He holds B.S. and M.S. degrees in Electrical Engineering and Computer Science from MIT, and a Ph.D. from Stanford.
Laurence J. Marton, MD
Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation, and on the Board of Directors of Cancer Commons, Rapid Science, and the Bay Area American Committee for the Weizmann Institute of Science. In the for-profit sector, he serves on the Board of Directors of Cellsonics, Dategra, Matternet, Microsonic Systems, Pathologica, RenovoRx, TOMA Biosciences, and xCures; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Ciitizen and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine.
Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University.
Frank McCormick, PhD, FRS, DSc (Hon)
Frank McCormick, PhD, FRS, DSc (Hon), was Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization that is one of the largest cancer centers in the Western U.S, and he was also Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his BSc in biochemistry from the University of Birmingham (1972) and his PhD in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S at the State University of New York at Stony Brook and in London, UK, at the Imperial Cancer Research Fund. He has been a fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice-President of Research, 1990-91) and Chiron Corporation, where he was a vice-president of research from 1991-92. In 1992, he founded Onyx Pharmaceuticals and served as its chief scientific officer until 1996. Dr. McCormick’s current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies. In addition to his positions held at UCSF, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF’s Department of Microbiology and Immunology. Dr. McCormick is the author of more than 270 scientific publications.
Gladys H. Monroy, PhD, JD
Gladys Monroy is Senior Partner at Morrison Foerster. Her practice includes strategic counseling, comprehensive patent portfolio management, interferences, reexaminations, and reissues. Dr. Monroy represents companies of all sizes in the areas of patent prosecution and technology transfers, involving many technologies within the field of life science. Dr. Monroy has previously held numerous leadership positions in intellectual property law associations, such as President and Board of Directors member of the Silicon Valley Intellectual Property Law Association, and Executive Committee member of the California State Bar Intellectual Property Section. She has received many honors, including being elected to the IP Law & Business Patent Prosecution Hall of Fame and being named by Chambers Women in Law as Intellectual Property Lawyer of the Year.
Prior to her career in law, Dr. Monroy was a post-doctoral fellow at the Einstein College of Medicine and an Assistant Professor of Microbiology at New York Medical College. She received her MS and PhD in biochemistry from NYU.
Heather Rangel is a Partner with Deloitte in San Jose, where she serves as Deloitte’s global leader for a leading technology company. In this roll, she coordinates a large cross-functional team delivering services and creating alliances to bring to market. Heather is also the Technology Sector Leader for Deloitte Tax in the U.S., building client relationships within the sector and delivering sector perspective to Deloitte professionals and clients. In her 18 years as a management consultant, she has delivered solutions to the technology, media and entertainment sectors, predominantly in the areas of global expansion, mobility of talent, international HR strategy and process improvement.
Heather is an inspirational leader, a frequent public speaker, and a strong advocate for women in business and technology.
Heather is the mother of two teenagers and that is her favorite role. She is an avid reader, competitive swimmer, adventurous traveler, and passionate supporter of the arts—especially documentary films focusing on the most important economic and social issues of our time. Heather founded the Shine Project, an initiative that continues to shine the light of those who have lost their lives to cancer through its support of Cancer Commons.
Edgar D. Staren, MD, PhD, MBA
Edgar D. Staren, MD, PhD, MBA is President of TransMed7, LLC and President of its subsidiary, Martinet Medical, LLC, minimal access medical technology companies addressing patient needs from diagnosis to therapy. Most recently he served as Professor of Surgery, Vice President and Executive Director for Cancer Services at Wake Forest University Baptist Medical Center, and Deputy Director for Clinical Affairs of its Comprehensive Cancer Center. He is a graduate of Loyola University School of Medicine and received his general surgery training and surgical oncology fellowship at Rush University Medical Center and Cook County Hospitals. Additional graduate education included a PhD in immunology/microbiology from Rush and an MBA from Benedictine University.
After his training, Dr. Staren remained as a faculty member at Rush and held positions as Professor of General Surgery and Associate Dean for Medical Student Programs. He subsequently served as Professor and Chairman of Surgery at the Medical College of Ohio and Medical Director of the MCO Cancer Institute, CEO of CTCA Medicine and Science, as well as, CEO of Ashion PMed Management, an outgrowth of the Translational Genomics Research Institute (TGen).
Dr. Staren is a member of numerous academic organizations and has published nearly 300 scientific works including more than 150 manuscripts, 80+ abstracts, 45 book chapters, and 12 books.
Ted Driscoll, PhD
Dr. Ted Driscoll joined Decheng Capital in October, 2016. Prior to joining Decheng, Dr. Driscoll was a Partner at Claremont Creek Ventures leading its efforts in Digital Healthcare and Diagnostics. He led the first investments in Natera (IPOed in 2015), AssureX Health (acquired by Myriad Genetics for $410M) and GeneWeave Biosciences (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader or founder of five startups. His first startup, International Imaging Systems, pioneered the first Digital Subtractive Angiography machines. He then led the technical team at Identix that pioneered the first digital fingerprint recognition which is now used in devices such as the iPhone. Identix went public in 1985. At his next startup, Diasonics, he led the team that created the world’s first MRI scanners, as Senior VP of Engineering and R&D. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company went public in 1992 and was then purchased by Takai Hospital Supply. His last startup was Be Here Technologies, a 360degree imaging company. This technology was purchased by and incorporated into Google Streetview. During his startup experience he was the inventor of over 50 patents. On the side he served as an elected Councilmember of his home town, Portola Valley, for 20 years and served five terms as Mayor. He graduated from Stanford with a Ph.D. in Digital Imaging, and previously received a Masters in Computer Graphics and a Masters in Regional Planning from Harvard, and a BA from the University of Pennsylvania.
Mikhail Gishizky, PhD, Executive Vice President R&D, Trellis Bioscience
Dick Levy, retired Chairman and CEO, Varian Medical, and former Chairman, Sutter Health
Peter Yu, MD, Physician-in-Chief Hartford HealthCare Cancer Institute, Past President, American Association of Clinical Oncology
William Miller, PhD, former Provost, Stanford University, and former President, SRI International
Rob Rodin, former CEO, Marshall Industries
William Wong, PhD, former EVP and GM, Merchant Solutions Group, Net Deposit and former Executive Director, Cancer Commons
William Brody, MD, PhD, former President Johns Hopkins University, and Salk Institute